BoneOscopy technology has broad applications in oncology, particularly in the treatment of metastatic bone cancers. It offers an innovative approach to daily cancer monitoring, potentially leading to reduced treatment duration, better patient outcomes, and the ability to tailor treatments dynamically to individual patient responses.
Within 5 years
BoneOscopy will offer an improved outcome to all metastatic patients treated with PRT, with its personalised monitoring approach of the treatment.
Within 10 years
BoneOscopy will have a major impact on PRT patients, leading to a significant reduction in the health burden within Europe and worldwide, an improved quality of life for patients, lower costs for health systems and improved sustainability of healthcare.
Daily treatment evaluation
BoneOscopy will offer patients and clinicians an evidence-based decision-making approach with early response assessment of the treatments, a reduction of the treatment toxicity and consequently an improved quality of life and better life expectancy.
Funded by the European Union and supported by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 101185141. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.
Contact us
Copyright © 2025 | accelopment Schweiz AG | All Rights Reserved · Read our Privacy Policy.